Acidophil is named after its co-founders: Nobel Laureate Sydney Brenner (1927-2019), and scientist, entrepreneur, and investor Philip Goelet.
Acidophil is an innovation company that uses technical and business information together with bio-chemical capabilities to create, manage and co-finance new product opportunities and biotechnology businesses in agriculture, animal health and human health.
Acidophil takes a global approach to innovation, management and investment that reflects the international perspective of its team and founders. Acidophil exploits a virtual business development model to enable capital efficient innovation in collaboration with scientists, entrepreneurs, corporations and investors who are interested in addressing global market needs.
Companies created, managed and co-financed by Acidophil include Evobiotics (discovery and development of safe, novel, resistance-breaking antimicrobial compounds to treat bacterial & fungal infections in humans), Chalante (developing parasiticides for companion animals that address unmet needs in animal health), AgriMetis (developing sustainable crop protection products), Population Genetic Technologies (novel technologies enhancing next generation genomic sequencing), Corridor Pharmaceuticals (developing arginase inhibitors for the treatment of endothelial disorders) and ZuvaSyntha (biochemical production of specialty and industrial chemicals).